Why Exelixis Is Ready to Rebound
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis has earned a respected four-star ranking.
With that in mind, let's take a closer look at Exelixis and see what CAPS investors are saying about the stock right now.
South San Francisco, Calif. (1994)
Co-Founder/Chairman Dr. Stelios Papadopoulos
Trailing-12-Month Return on Equity
$411.4 million / $335.7 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 2,642 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.
Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, [Exelixis] will take off.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Exelixis may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Exelixis Is Ready to Rebound originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.